Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study

Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study

BackgroundThe treatment of cancer has brought about a paradigm shift with the introduction of immune checkpoint blockade (ICB) therapy, which is mostly dependent on inhibiting PD-1/PD-L1 and CTLA-4. However, recent studies have shown limited efficacy of this treatment in esophageal squamous cell car...

Full description

Saved in:
Bibliographic Details
Main Authors: Chengzhi Ding, Yahao Zhang, Tian Xia, Jiwei Li, Wenjian Yao, Quan Zhang, Zhijun Han, Jianjun Wang, Zhikun Cao, Jinlong Hu, Li Wei
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
esophageal squamous cell carcinoma
the BTLA inhibitor
toripalimab
esophagectomy
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542877/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1542877/full

Similar Items